Skip to content

Source filing unavailable

Q3 2023 · —
Revenue—
Net Income-$22.85Mno prior Q3 2022 on fileN/M vs Q2 2023
EPS Diluted-$38.23no prior Q3 2022 on fileno prior Q2 2023 on file
Operating Income-$9,530,000—

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

no prior Q3 2022 on file

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Bicara Therapeutics Inc. · CIK 2023658 · Engraved from SEC EDGAR